Our findings are relevant and important, since CD71+ erythroid cells can have both a positive regulatory effect (in inflammatory and autoimmune diseases, pregnancy, and the neonatal period) and a negative regulatory effect (in cancer, infectious diseases, and anemia) on the mechanisms of the immune system [15]. The gene discussed is TFRC; the disease is cancer.